Hypodermic Syringes & Needles Market - By Type, By Usability, By Application, By End-use & Forecast, 2023 - 2032
由于慢性病激增，全球皮下注射器和针头市场预计到 2032 年将出现显着增长。
根据纽约州卫生部的数据，心脏病每年在美国造成约 697,000 人死亡，占死亡人数的五分之一。 不断增加的疾病负担正在增加手术的数量，进一步增加了对皮下注射器和针头的需求。
基于易用性，由于市场参与者对新产品创新的不断努力，预计到 2032 年可重复使用部分皮下注射器和针头行业将实现可观的利润。 此外，可重复使用的皮下注射器和针头适用于注射抗生素和疫苗。 此外，政府部门对大规模疫苗接种的投资显着增加，也可能进一步推动该行业的增长。
从应用的角度来看，随着政府当局越来越关注公共安全的疫苗接种，疫苗接种领域的皮下注射器和针头行业将从 2023 年到 2032 年实现显着的复合年增长率。预计将在 事实上，2022 年 1 月，阿根廷发起了针对 COVID-19 的全国疫苗接种运动，以恢復学校的面对面授课。 同样，新兴经济体政府加大力度抗击传染病，预计将为市场扩张铺平道路。
到 2032 年，诊断中心皮下注射器和针头市场的最终用途预计估值将超过 20 亿美元。 微创外科手术的普及显着增加，例如用于组织样本病理分析的核心针活检，增加了诊断中心对皮下注射器和针头的需求。 此外，这些仪器可以通过精确定位手术部位来获取组织样本，从而减少术后并发症并加快恢復速度。
按地区划分，从 2023 年到 2032 年，亚太地区的皮下注射器和针头行业预计将以超过 4.5% 的复合年增长率增长。 易患疾病的老年人口越来越多，就诊频率也越来越高，对我们的产品产生了强劲的需求。 据世界卫生组织称，到 2040 年，中国 28% 的人口，即 4.02 亿人，将超过 60 岁。
Global Hypodermic Syringes & Needles Market is anticipated to register remarkable gains through 2032 on account of the surging prevalence of chronic disorders. As per the New York State Department of Health, in the U.S., heart disease causes around 697,000 deaths every year, which accounts for 1 in every 5 deaths. The growing disease burden has increased the number of surgeries, further escalating the need for hypodermic syringes & needles.
Overall, the hypodermic syringes & needles market is segmented in terms of type, usability, application, end-use, and region.
Based on usability, the hypodermic syringes & needles industry from the reusable segment is slated to register considerable gains through 2032, owing to the growing efforts of market players on new product innovations. Moreover, hypodermic reusable syringes and needles work well for the administration of injectable antibiotics and vaccines. In addition, a commendable rise in investments by government authorities in mega vaccination drives may further bolster segment growth.
In terms of application, the hypodermic syringes & needles industry from the vaccination segment is expected to grow at a substantial CAGR from 2023 to 2032, owing to the growing focus of government authorities on vaccination drives for public safety. In fact, in January 2022, Argentina implemented a National Vaccination Campaign in an effort to combat COVID-19 to restore in-person classes in schools. Likewise, the growing efforts of governments of developing economies to fight against infectious diseases are likely to pave the way for market expansion.
With respect to end-use, the hypodermic syringes & needles market from the diagnostic centers segment is slated to record a valuation of over USD 2 billion by 2032. A remarkable rise in the popularity of minimally invasive surgical procedures, such as core needle biopsy for pathological analysis of tissue samples, has bolstered the need for hypodermic syringes & needles in diagnostic centers. Moreover, these devices help obtain tissue samples by precisely targeting the area to be operated, leading to fewer postoperative complications and quick recovery.
From the regional perspective, the Asia Pacific hypodermic syringes & needles industry is poised to grow at over 4.5% CAGR from 2023 to 2032. The rising geriatric population, which is highly susceptible to diseases, has increased the frequency of visits to medical facilities, creating a strong demand for the product. As per WHO, an estimated 402 million people, which makes up 28% of the population in China will be over the age of 60 years by 2040.